Physician profile
Steven Yeh
NPI 1689851958
$288,785.16
in general payments reported to CMS, 2019-2025
24 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $9,506 · 2021: $25K · 2022: $58K · 2023: $71K · 2024: $71K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $151K · Travel and Lodging: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $9,360 · Honoraria: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150,566.50 |
| Travel and Lodging | $17,244.73 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,193.75 |
| Food and Beverage | $9,360.14 |
| Honoraria | $2,025.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $118,214.88 | 2022-2025 | Xipere, Stellaris Elite, Stellaris |
| Alcon Vision LLC | $59,195.82 | 2019-2025 | Constellation, Unity, Ngenuity |
| Apellis Pharmaceuticals, INC. | $45,644.50 | 2023-2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23,806.24 | 2019-2021 | |
| Genentech USA, INC. | $22,435.32 | 2021-2025 | Susvimo, Vabysmo |
| Eyepoint US, INC. | $4,527.93 | 2022-2023 | |
| Sanofi US Services INC. | $3,969.00 | 2024 | |
| Abbvie INC. | $3,376.44 | 2022-2025 | |
| Lupin INC. | $2,241.00 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $2,146.46 | 2025 | Yutiq, Purified Cortrophin Gel |
| Allergan, INC. | $1,029.38 | 2021 | |
| Genentech, INC. | $349.16 | 2021-2025 | |
| Carl Zeiss Meditec USA, INC. | $313.95 | 2022-2024 | |
| Alimera Sciences, INC. | $285.06 | 2023-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $249.46 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $205.93 | 2025 | Izervay |
| Biogen, INC. | $176.77 | 2022-2024 | Byooviz |
| Janssen Pharmaceuticals, INC | $135.00 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $106.82 | 2023 | Cequa |
| Dompe US, INC. | $83.86 | 2025 | Oxervate |
| Coherus Oncology, INC. | $78.31 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $66.66 | 2025 | Eylea Hd, Eylea |
| Amgen INC. | $22.22 | 2024 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.